McGuire, D. Okay. et al. Affiliation of SGLT2 inhibitors with cardiovascular and kidney outcomes in sufferers with kind 2 diabetes: a meta-analysis. JAMA Cardiol. 6, 148–158 (2021).
US Nationwide Library of Medication. ClinicalTrials.gov https://clinicaltrials.gov/research/NCT04564742 (2023).
US Nationwide Library of Medication. ClinicalTrials.gov https://clinicaltrials.gov/research/NCT04509674 (2023).
McDonagh, T. A. et al. 2021 ESC pointers for the prognosis and therapy of acute and power coronary heart failure. Eur. Coronary heart J. 42, 3599–3726 (2021).
Heidenreich, P. A. et al. 2022 AHA/ACC/HFSA guideline for the administration of coronary heart failure: government abstract: a report of the American Faculty of Cardiology/American Coronary heart Affiliation Joint Committee on Scientific Follow Pointers. J. Am. Coll. Cardiol. 79, 1757–1780 (2022).
UK Kidney Affiliation. UK Kidney Affiliation medical observe guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney illness.https://ukkidney.org/websites/renal.org/recordsdata/UKKApercent20guideline_SGLT2ipercent20inpercent20adultspercent20withpercent20kidneypercent20diseasepercent20v1percent2020.10.21.pdf (2021).
Cowie, M. R. & Fisher, M. SGLT2 inhibitors: mechanisms of cardiovascular profit past glycaemic management. Nat. Rev. Cardiol. 17, 761–772 (2020).
Youssef, M. E. et al. Unlocking the total potential of SGLT2 inhibitors: increasing purposes past glycemic management. Int. J. Mol. Sci. 24, 6039 (2023).
Curthoys, N. P. & Moe, O. W. Proximal tubule perform and response to acidosis. Clin. J. Am. Soc. Nephrol. 9, 1627–1638 (2014).
Hou, Y. C., Zheng, C. M., Yen, T. H. & Lu, Okay. C. Molecular mechanisms of SGLT2 inhibitor on cardiorenal safety. Int. J. Mol. Sci. 21, 7833 (2020).
Heerspink, H. J., Perkins, B. A., Fitchett, D. H., Husain, M. & Cherney, D. Z. Sodium glucose cotransporter 2 inhibitors within the therapy of diabetes mellitus: cardiovascular and kidney results, potential mechanisms, and medical purposes. Circulation 134, 752–772 (2016).
Cherney, D. Z., Kanbay, M. & Lovshin, J. A. Renal physiology of glucose dealing with and therapeutic implications. Nephrol. Dial. Transpl. 35, i3–i12 (2020).
Zaccardi, F. et al. Efficacy and security of sodium-glucose co-transporter-2 inhibitors in kind 2 diabetes mellitus: systematic assessment and community meta-analysis. Diabetes Obes. Metab. 18, 783–794 (2016).
DeFronzo, R. A. et al. Characterization of renal glucose reabsorption in response to dapagliflozin in wholesome topics and topics with kind 2 diabetes. Diabetes Care 36, 3169–3176 (2013).
Ojima, A., Matsui, T., Nishino, Y., Nakamura, N. & Yamagishi, S. Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic results on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm. Metab. Res. 47, 686–692 (2015).
Yang, L. et al. Dapagliflozin alleviates superior glycation finish product induced podocyte harm by means of AMPK/mTOR mediated autophagy pathway. Cell Sign. 90, 110206 (2022).
Thomas, M. C. & Cherney, D. Z. I. The actions of SGLT2 inhibitors on metabolism, renal perform and blood stress. Diabetologia 61, 2098–2107 (2018).
Cravedi, P. & Remuzzi, G. Pathophysiology of proteinuria and its worth as an consequence measure in power kidney illness. Br. J. Clin. Pharmacol. 76, 516–523 (2013).
Karg, M. V. et al. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content material: a randomised managed trial. Cardiovasc. Diabetol. 17, 5 (2018).
Hallow, Okay. M., Helmlinger, G., Greasley, P. J., McMurray, J. J. V. & Boulton, D. W. Why do SGLT2 inhibitors scale back coronary heart failure hospitalization? A differential quantity regulation speculation. Diabetes Obes. Metab. 20, 479–487 (2018).
Uthman, L. et al. Class results of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, decreasing of cytosolic Na(+) and vasodilation. Diabetologia 61, 722–726 (2018).
Trum, M., Riechel, J. & Wagner, S. Cardioprotection by SGLT2 inhibitors-does all of it come right down to Na+? Int. J. Mol. Sci. 22, 7976 (2021).
Peyton, Okay. J., Behnammanesh, G., Durante, G. L. & Durante, W. Canagliflozin inhibits human endothelial cell irritation by means of the induction of heme oxygenase-1. Int. J. Mol. Sci. 23, 8777 (2022).
Campbell, N. Okay., Fitzgerald, H. Okay. & Dunne, A. Regulation of irritation by the antioxidant haem oxygenase 1. Nat. Rev. Immunol. 21, 411–425 (2021).
Consoli, V., Sorrenti, V., Grosso, S. & Vanella, L. Heme oxygenase-1 signaling and redox homeostasis in physiopathological circumstances. Biomolecules 11, 589 (2021).
Gager, G. M. et al. Results of SGLT2 inhibitors on ion homeostasis and oxidative stress related mechanisms in coronary heart failure. Biomed. Pharmacother. 143, 112169 (2021).
Oraby, M. A., El-Yamany, M. F., Safar, M. M., Assaf, N. & Ghoneim, H. A. Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats. Biomed. Pharmacother. 109, 910–920 (2019).
Ye, Y., Bajaj, M., Yang, H. C., Perez-Polo, J. R. & Birnbaum, Y. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the event of diabetic cardiomyopathy in mice with kind 2 diabetes. Additional augmentation of the consequences with saxagliptin, a DPP4 inhibitor. Cardiovasc. Medicine Ther. 31, 119–132 (2017).
Niu, Y. et al. Canagliflozin ameliorates NLRP3 inflammasome-mediated irritation by means of inhibiting NF-kappaB signaling and upregulating Bif-1. Entrance. Pharmacol. 13, 820541 (2022).
Abdollahi, E. et al. Dapagliflozin exerts anti-inflammatory results through inhibition of LPS-induced TLR-4 overexpression and NF-kappaB activation in human endothelial cells and differentiated macrophages. Eur. J. Pharmacol. 918, 174715 (2022).
Skrabic, R. et al. SGLT2 inhibitors in power kidney illness: from mechanisms to medical observe. Biomedicines 10, 2458 (2022).
Androutsakos, T. et al. SGLT-2 inhibitors in NAFLD: increasing their function past diabetes and cardioprotection. Int. J. Mol. Sci. 23, 3107 (2022).
Lupsa, B. C., Kibbey, R. G. & Inzucchi, S. E. Ketones: the double-edged sword of SGLT2 inhibitors? Diabetologia 66, 23–32 (2023).
Ferrannini, E. et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in topics with out diabetes and sufferers with kind 2 diabetes. Diabetes 65, 1190–1195 (2016).
Youm, Y. H. et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory illness. Nat. Med. 21, 263–269 (2015).
Swanson, Okay. V., Deng, M. & Ting, J. P. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477–489 (2019).
Tomita, I. et al. SGLT2 inhibition mediates safety from diabetic kidney illness by selling ketone body-induced mTORC1 inhibition. Cell Metab. 32, 404–419.e6 (2020).
Heerspink, H. J. L. et al. Canagliflozin reduces irritation and fibrosis biomarkers: a possible mechanism of motion for helpful results of SGLT2 inhibitors in diabetic kidney illness. Diabetologia 62, 1154–1166 (2019).
Zhang, Y. et al. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary harm and fibrosis by a vascular endothelial development factor-dependent pathway after renal harm in mice. Kidney Int. 94, 524–535 (2018).
Hesp, A. C. et al. The function of renal hypoxia within the pathogenesis of diabetic kidney illness: a promising goal for newer renoprotective brokers together with SGLT2 inhibitors? Kidney Int. 98, 579–589 (2020).
Lauritsen, Okay. M. et al. SGLT2 inhibition doesn’t have an effect on myocardial fatty acid oxidation or uptake, however reduces myocardial glucose uptake and blood move in people with kind 2 diabetes: a randomized double-blind, placebo-controlled crossover trial. Diabetes 70, 800–808 (2021).
Gao, Y. M. et al. Cardiorenal safety of SGLT2 inhibitors – views from metabolic reprogramming. EBioMedicine 83, 104215 (2022).
Sano, M. A brand new class of medication for coronary heart failure: SGLT2 inhibitors scale back sympathetic overactivity. J. Cardiol. 71, 471–476 (2018).
Sano, M. Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress accountable for sympathetic activation. Ther. Adv. Cardiovasc. Dis. 14, 1753944720939383 (2020).
Scheen, A. J. Impact of SGLT2 inhibitors on the sympathetic nervous system and blood stress. Curr. Cardiol. Rep. 21, 70 (2019).
Li, T., Chen, Y., Gua, C. & Wu, B. Elevated oxidative stress and irritation in hypothalamic paraventricular nucleus are related to sympathetic excitation and hypertension in rats uncovered to power intermittent hypoxia. Entrance. Physiol. 9, 840 (2018).
Ye, S., Zhong, H., Yanamadala, S. & Campese, V. M. Oxidative stress mediates the stimulation of sympathetic nerve exercise within the phenol renal harm mannequin of hypertension. Hypertension 48, 309–315 (2006).
Manosroi, W., Danpanichkul, P. & Atthakomol, P. Impact of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin ranges in diabetes mellitus kind 2 sufferers: a scientific assessment and meta-analysis. Sci. Rep. 12, 19603 (2022).
Seidu, S., Kunutsor, S. Okay., Topsever, P. & Khunti, Okay. Advantages and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in sufferers with kind 2 diabetes: a scientific assessment and meta-analysis of randomized managed trials. Endocrinol. Diabetes Metab. 5, e00303 (2022).
Neuen, B. L. et al. SGLT2 inhibitors for the prevention of kidney failure in sufferers with kind 2 diabetes: a scientific assessment and meta-analysis. Lancet Diabetes Endocrinol. 7, 845–854 (2019).
Iacobellis, G. & Gra-Menendez, S. Results of dapagliflozin on epicardial fats thickness in sufferers with kind 2 diabetes and weight problems. Weight problems 28, 1068–1074 (2020).
Camarena, V. et al. Novel atherogenic pathways from the differential transcriptome evaluation of diabetic epicardial adipose tissue. Nutr. Metab. Cardiovasc. Dis. 27, 739–750 (2017).
Díaz-Rodríguez, E. et al. Results of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine manufacturing, and differentiation capability. Cardiovasc. Res. 114, 336–346 (2018).
Durante, W., Behnammanesh, G. & Peyton, Okay. J. Results of sodium-glucose co-transporter 2 inhibitors on vascular cell perform and arterial transforming. Int J. Mol. Sci. 22, 8786 (2021).
Lescano, C. H. et al. The sodium-glucose cotransporter-2 (SGLT2) inhibitors synergize with nitric oxide and prostacyclin to scale back human platelet activation. Biochem. Pharmacol. 182, 114276 (2020).
Dhingra, N. Okay. et al. SGLT2 inhibitors and cardiac remodelling: a scientific assessment and meta-analysis of randomized cardiac magnetic resonance imaging trials. ESC Coronary heart Fail. 8, 4693–4700 (2021).
Herrington, W. G. et al. Cardiac, renal, and metabolic results of sodium-glucose co-transporter 2 inhibitors: a place paper from the European Society of Cardiology ad-hoc activity drive on sodium-glucose co-transporter 2 inhibitors. Eur. J. Coronary heart Fail. 23, 1260–1275 (2021).
Cefalu, W. T. et al. Cardiovascular outcomes trials in kind 2 diabetes: the place will we go from right here? Reflections from a diabetes care editors’ knowledgeable discussion board. Diabetes Care 41, 14–31 (2018).
Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in kind 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).
Wanner, C. et al. Empagliflozin and development of kidney illness in kind 2 diabetes. N. Eng. J. Med. 375, 323–334 (2016).
Nuffield Division of Inhabitants Well being Renal Research Group. SGLT2 inhibitor Meta-Evaluation Cardio-Renal Trialists’ Consortium. Influence of diabetes on the consequences of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of huge placebo-controlled trials. Lancet 400, 1788–1801 (2022).
Perkovic, V. et al. Canagliflozin and renal outcomes in kind 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).
Heerspink, H. J. L. et al. Dapagliflozin in sufferers with power kidney illness. N. Engl. J. Med. 383, 1436–1446 (2020).
Herrington, W. G. et al. Empagliflozin in sufferers with power kidney illness. N. Engl. J. Med. 388, 117–127 (2023).
Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in coronary heart failure. N. Engl. J. Med. 383, 1413–1424 (2020).
McMurray, J. J. V. et al. Dapagliflozin in sufferers with coronary heart failure and diminished ejection fraction. N. Engl. J. Med. 381, 1995–2008 (2019).
Anker, S. D. et al. Empagliflozin in coronary heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451–1461 (2021).
Solomon, S. D. et al. Dapagliflozin in coronary heart failure with mildly diminished or preserved ejection fraction. N. Engl. J. Med. 387, 1089–1098 (2022).
US Nationwide Library of Medication. ClinicalTrials.gov https://clinicaltrials.gov/research/NCT05374291 (2023).
US Nationwide Library of Medication. ClinicalTrials.gov https://clinicaltrials.gov/research/NCT03819153 (2024).
US Nationwide Library of Medication. ClinicalTrials.gov https://clinicaltrials.gov/research/NCT05254002 (2024).
Heerspink, H. J. L. et al. Change in albuminuria as a surrogate endpoint for development of kidney illness: a meta-analysis of therapy results in randomised medical trials. Lancet Diabetes Endocrinol. 7, 128–139 (2019).
Heerspink, H. J. et al. Canagliflozin slows development of renal perform decline independently of glycemic results. J. Am. Soc. Nephrol. 28, 368–375 (2017).
Neal, B. et al. Canagliflozin and cardiovascular and renal occasions in kind 2 diabetes. N. Eng. J. Med. 377, 644–657 (2017).
Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in kind 2 diabetes. N. Eng. J. Med. 380, 347–357 (2019).
Cannon, C. P. et al. Cardiovascular outcomes with ertugliflozin in kind 2 diabetes. N. Engl. J. Med. 383, 1425–1435 (2020).
Bhatt, D. L. et al. Sotagliflozin in sufferers with diabetes and power kidney illness. N. Engl. J. Med. 384, 129–139 (2020).
Mosenzon, O. et al. Results of dapagliflozin on growth and development of kidney illness in sufferers with kind 2 diabetes: an evaluation from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 7, 606–617 (2019).
Persson, F. et al. Efficacy and security of dapagliflozin by baseline glycemic standing: a prespecified evaluation from the DAPA-CKD trial. Diabetes Care 44, 1894–1897 (2021).
Afsar, B. et al. Sodium–glucose cotransporter inhibition in polycystic kidney illness: truth or fiction. Clin. Kidney J. 15, 1275–1283 (2022).
Ujjawal, A., Schreiber, B. & Verma, A. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what’s the proof? Ther. Adv. Endocrinol. Metab. 13, 20420188221090001 (2022).
Neuen, B. L. et al. Impact of canagliflozin on renal and cardiovascular outcomes throughout totally different ranges of albuminuria: knowledge from the CANVAS Program. J. Am. Soc. Nephrol. 30, 2229–2242 (2019).
Jardine, M. et al. Kidney, cardiovascular, and security outcomes of canagliflozin in response to baseline albuminuria: a CREDENCE secondary evaluation. Clin. J. Am. Soc. Nephrol. 16, 384–395 (2021).
Heerspink, H. J. L. et al. Impact of dapagliflozin on the speed of decline in kidney perform in sufferers with power kidney illness with and with out kind 2 diabetes: a prespecified evaluation from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 9, 743–754 (2021).
Inker, L. A. et al. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat. Med. 29, 1867–1876 (2023).
Kraus, B. J. et al. Characterization and implications of the preliminary estimated glomerular filtration charge ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin within the EMPA-REG OUTCOME trial. Kidney Int. 99, 750–762 (2021).
Jongs, N. et al. Correlates and penalties of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in sufferers with CKD. J. Am. Soc. Nephrol. 33, 2094–2107 (2022).
Sridhar, V. S., Tuttle, Okay. R. & Cherney, D. Z. I. We will lastly cease worrying about SGLT2 inhibitors and acute kidney harm. Am. J. Kidney Dis. 76, 454–456 (2020).
Neuen, B. L. et al. Sodium-glucose cotransporter 2 inhibitors and danger of hyperkalemia in individuals with kind 2 diabetes: a meta-analysis of particular person participant knowledge from randomized, managed trials. Circulation 145, 1460–1470 (2022).
Charlwood, C., Chudasama, J., Darling, A. L., Logan Ellis, H. & Whyte, M. B. Impact of sodium-glucose co-transporter 2 inhibitors on plasma potassium: a meta-analysis. Diabetes Res. Clin. Pract. 196, 110239 (2023).
Halden, T. A. S. et al. Efficacy and security of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 42, 1067–1074 (2019).
Oliveras, L., Montero, N. & Cruzado, J. M. Looking out within the maze: sodium–glucose cotransporter-2 inhibitors in kidney transplant recipients to enhance survival. Clin. Kidney J. 16, 909–913 (2023).
Maffei, P., Bettini, S., Busetto, L. & Dassie, F. SGLT2 inhibitors within the administration of kind 1 diabetes (T1D): an replace on present proof and proposals. Diabetes Metab. Syndr. Obes. 16, 3579–3598 (2023).
Inzucchi, S. E. et al. Enchancment in cardiovascular outcomes with empagliflozin is unbiased of glycemic management. Circulation 138, 1904–1907 (2018).
Inzucchi, S. E. et al. Cardiovascular good thing about empagliflozin throughout the spectrum of cardiovascular danger issue management within the EMPA-REG OUTCOME trial. J. Clin. Endocrinol. Metab. 105, 3025–3035 (2020).
Tsai, P. C. et al. Impartial results of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive illness, or ischemic stroke: a meta-analysis of randomized managed trials. Cardiovasc. Diabetol. 22, 57 (2023).
Sattar, N. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in sufferers with kind 2 diabetes: a scientific assessment and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 9, 653–662 (2021).
Lam, C. S. P. et al. Efpeglenatide and medical outcomes with and with out concomitant sodium-glucose cotransporter-2 inhibition use in kind 2 diabetes: exploratory evaluation of the AMPLITUDE-O trial. Circulation 145, 565–574 (2022).
Pitt, B. & Bhatt, D. L. Does SGLT1 inhibition add profit to SGLT2 inhibition in kind 2 diabetes? Circulation 144, 4–6 (2021).
Zannad, F. et al. SGLT2 inhibitors in sufferers with coronary heart failure with diminished ejection fraction: a meta-analysis of the EMPEROR-Decreased and DAPA-HF trials. Lancet 396, 819–829 (2020).
Butler, J. et al. Empagliflozin and health-related high quality of life outcomes in sufferers with coronary heart failure with diminished ejection fraction: the EMPEROR-Decreased trial. Eur. Coronary heart J. 42, 1203–1212 (2021).
Vaduganathan, M. et al. SGLT-2 inhibitors in sufferers with coronary heart failure: a complete meta-analysis of 5 randomised managed trials. Lancet 400, 757–767 (2022).
Butler, J. et al. Empagliflozin, well being standing, and high quality of life in sufferers with coronary heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation 145, 184–193 (2022).
Kosiborod, M. N. et al. Impact of dapagliflozin on well being standing in sufferers with preserved or mildly diminished ejection fraction. J. Am. Coll. Cardiol. 81, 460–473 (2023).
McDonagh, T. A. et al. 2023 targeted replace of the 2021 ESC pointers for the prognosis and therapy of acute and power coronary heart failure. Eur. Coronary heart J. 44, 3627–3639 (2023).
Voors, A. A. et al. The SGLT2 inhibitor empagliflozin in sufferers hospitalized for acute coronary heart failure: a multinational randomized trial. Nat. Med. 28, 568–574 (2022).
Bhatt, D. L. et al. Sotagliflozin in sufferers with diabetes and up to date worsening coronary heart failure. N. Engl. J. Med. 384, 117–128 (2021).
Berg, D. D. et al. Time to medical good thing about dapagliflozin and significance of prior coronary heart failure hospitalization in sufferers with coronary heart failure with diminished ejection fraction. JAMA Cardiol. 6, 499–507 (2021).
Vaduganathan, M. et al. Time to medical good thing about dapagliflozin in sufferers with coronary heart failure with mildly diminished or preserved ejection fraction: a prespecified secondary evaluation of the DELIVER randomized medical trial. JAMA Cardiol. 7, 1259–1263 (2022).
Provenzano, M. et al. POS-255 Impact of dapagliflozin on blood stress in sufferers with CKD: a pre-specified evaluation from DAPA-CKD. Kidney Int. Rep. 7, S112 (2022).
Ye, N. et al. Blood stress results of canagliflozin and medical outcomes in kind 2 diabetes and power kidney illness. Circulation 143, 1735–1749 (2021).
Del Prato, S. et al. Lengthy-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on remedy to metformin in sufferers with kind 2 diabetes: 4-year knowledge. Diabetes Obes. Metab. 17, 581–590 (2015).
Cheong, A. J. Y. et al. SGLT inhibitors on weight and physique mass: a meta-analysis of 116 randomized-controlled trials. Weight problems 30, 117–128 (2022).
Cai, X. et al. The affiliation between the dosage of SGLT2 inhibitor and weight discount in kind 2 diabetes sufferers: a meta-analysis. Weight problems 26, 70–80 (2018).
Inzucchi, S. E. et al. Empagliflozin therapy results throughout classes of baseline HbA1c, physique weight and blood stress as an add-on to metformin in sufferers with kind 2 diabetes. Diabetes Obes. Metab. 23, 425–433 (2021).
Pan, R. et al. Impact of SGLT-2 inhibitors on physique composition in sufferers with kind 2 diabetes mellitus: a meta-analysis of randomized managed trials. PLoS ONE 17, e0279889 (2022).
Cefalu, W. T. et al. Efficacy and security of canagliflozin versus glimepiride in sufferers with kind 2 diabetes inadequately managed with metformin (CANTATA-SU): 52 week outcomes from a randomised, double-blind, part 3 non-inferiority trial. Lancet 382, 941–950 (2013).
Ridderstrale, M. et al. Comparability of empagliflozin and glimepiride as add-on to metformin in sufferers with kind 2 diabetes: a 104-week randomised, active-controlled, double-blind, part 3 trial. Lancet Diabetes Endocrinol. 2, 691–700 (2014).
Ferrannini, G. et al. Vitality steadiness after sodium-glucose cotransporter 2 inhibition. Diabetes Care 38, 1730–1735 (2015).
Mayne, Okay. J. et al. Results of empagliflozin on fluid overload, weight and blood stress in power kidney illness. J. Am. Soc. Nephrol. 35, 202–215 (2023).
Hollander, P. et al. Coadministration of canagliflozin and phentermine for weight administration in chubby and overweight people with out diabetes: a randomized medical trial. Diabetes Care 40, 632–639 (2017).
Frias, J. P. et al. Exenatide as soon as weekly plus dapagliflozin as soon as each day versus exenatide or dapagliflozin alone in sufferers with kind 2 diabetes inadequately managed with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, part 3, randomised managed trial. Lancet Diabetes Endocrinol. 4, 1004–1016 (2016).
Li, C., Luo, J., Jiang, M. & Wang, Okay. The efficacy and security of the mix remedy with GLP-1 receptor agonists and SGLT-2 inhibitors in kind 2 diabetes mellitus: a scientific assessment and meta-analysis. Entrance. Pharmacol. 13, 838277 (2022).
Lundkvist, P. et al. Dapagliflozin as soon as each day plus exenatide as soon as weekly in overweight adults with out diabetes: sustained reductions in physique weight, glycaemia and blood stress over 1 12 months. Diabetes Obes. Metab. 19, 1276–1288 (2017).
Rinella, M. E. et al. A multi-society Delphi consensus assertion on new fatty liver illness nomenclature. Hepatology 78, 1966–1986 (2023).
Dufour, J. F. et al. Present therapies and new developments in NASH. Intestine 71, 2123–2134 (2022).
Sinha, B., Datta, D. & Ghosal, S. Meta-analysis of the consequences of sodium glucose cotransporter 2 inhibitors in non-alcoholic fatty liver illness sufferers with kind 2 diabetes. JGH Open 5, 219–227 (2021).
Shao, S. C., Kuo, L. T., Chien, R. N., Hung, M. J. & Lai, E. C. SGLT2 inhibitors in sufferers with kind 2 diabetes with non-alcoholic fatty liver ailments: an umbrella assessment of systematic critiques. BMJ Open Diabetes Res Care 8, e001956 (2020).
Xing, B. et al. Results of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver illness in sufferers with kind 2 diabetes: a meta-analysis of randomized managed trials. J. Diabetes Investig. 11, 1238–1247 (2020).
Wei, Q., Xu, X., Guo, L., Li, J. & Li, L. Impact of SGLT2 inhibitors on kind 2 diabetes mellitus with non-alcoholic fatty liver illness: a meta-analysis of randomized managed trials. Entrance. Endocrinol. 12, 635556 (2021).
Wong, C. et al. Sodium-glucose co-transporter 2 inhibitors for non-alcoholic fatty liver illness in Asian sufferers with kind 2 diabetes: a meta-analysis. Entrance. Endocrinol. 11, 609135 (2020).
Taheri, H. et al. Impact of empagliflozin on liver steatosis and fibrosis in sufferers with non-alcoholic fatty liver illness with out diabetes: a randomized, double-blind, placebo-controlled trial. Adv. Ther. 37, 4697–4708 (2020).
Tobita, H. et al. Comparability of dapagliflozin and teneligliptin in nonalcoholic fatty liver illness sufferers with out kind 2 diabetes mellitus: a potential randomized research. J. Clin. Biochem. Nutr. 68, 173–180 (2021).
Spiazzi, B. F. et al. Sodium-glucose cotransporter-2 inhibitors and most cancers outcomes: a scientific assessment and meta-analysis of randomized managed trials. Diabetes Res. Clin. Pract. 198, 110621 (2023).
Kohler, S., Lee, J., George, J. T., Inzucchi, S. E. & Zinman, B. Bladder most cancers within the EMPA-REG OUTCOME trial. Diabetologia 60, 2534–2535 (2017).
Tang, H. et al. SGLT2 inhibitors and danger of most cancers in kind 2 diabetes: a scientific assessment and meta-analysis of randomised managed trials. Diabetologia 60, 1862–1872 (2017).
Abrahami, D. et al. Sodium-glucose cotransporter 2 inhibitors and the short-term danger of bladder most cancers: a global multisite cohort research. Diabetes Care 45, 2907–2917 (2022).
Hu, W. S. & Lin, C. L. Sufferers with diabetes with and with out sodium-glucose cotransporter-2 inhibitors use with incident most cancers danger. J. Diabetes Issues 37, 108468 (2023).
Wu, W. et al. SGLT2 inhibitor prompts the STING/IRF3/IFN-β pathway and induces immune infiltration in osteosarcoma. Cell Loss of life Dis. 13, 523 (2022).
Wang, Y. et al. SGLT2 inhibition restrains thyroid most cancers development through G1/S part transition arrest and apoptosis mediated by DNA harm response signaling pathways. Most cancers Cell Int. 22, 74 (2022).
Jiang, D. & Ma, P. Canagliflozin, characterised as a HDAC6 inhibitor, inhibits gastric most cancers metastasis. Entrance. Oncol. 12, 1057455 (2022).
Dutka, M. et al. SGLT-2 inhibitors in most cancers therapy – mechanisms of motion and rising new views. Cancers 14, 5811 (2022).
Schietzel, S. et al. Influence of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial. BMJ Open 12, e059073 (2022).
Balasubramanian, P. et al. Empagliflozin and decreased danger of nephrolithiasis: a possible new function for SGLT2 inhibition? J. Clin. Endocrinol. Metab. 107, e3003–e3007 (2022).
Bailey, C. J. Uric acid and the cardio-renal results of SGLT2 inhibitors. Diabetes Obes. Metab. 21, 1291–1298 (2019).
Banerjee, M., Pal, R., Maisnam, I., Chowdhury, S. & Mukhopadhyay, S. Serum uric acid decreasing and results of sodium-glucose cotransporter-2 inhibitors on gout: a meta-analysis and meta-regression of randomized managed trials. Diabetes Obes. Metab. 25, 2697–2703 (2023).
Packer, M. Alleviation of anemia by SGLT2 inhibitors in sufferers with CKD: mechanisms and outcomes of long-term placebo-controlled trials. Clin. J. Am. Soc. Nephrol., https://doi.org/10.2215/CJN.0000000000000362 (2023).
Singh, D. Okay., Winocour, P. & Farrington, Okay. Erythropoietic stress and anemia in diabetes mellitus. Nat. Rev. Endocrinol. 5, 204–210 (2009).
Okunrintemi, V., Mishriky, B. M., Powell, J. R. & Cummings, D. M. Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation within the cardiovascular and renal consequence trials. Diabetes Obes. Metab. 23, 276–280 (2021).
O’Hara, D. V. & Jardine, M. J. SGLT2 inhibitors could stop diabetes. Nat. Rev. Nephrol. 18, 203–204 (2022).
Kosiborod, M. N. et al. Dapagliflozin in sufferers with cardiometabolic danger elements hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, part 3 trial. Lancet Diabetes Endocrinol. 9, 586–594 (2021).
The RECOVERY Collaborative Group. Empagliflozin in sufferers admitted to hospital with COVID-19 (RECOVERY): a randomised, managed, open-label, platform trial. Lancet Diabetes Endocrinol. 11, 905–914 (2023).
ESC Press Workplace. SGLT2 inhibitors not linked with improved survival in hospitalised COVID-19 sufferers: SGLT2 inhibitors in COVID-19 meta-analysis offered in a Sizzling Line session in the present day at ESC Congress 2023 European Society of Cardiology https://www.escardio.org/The-ESC/Press-Workplace/Press-releases/SGLT2-inhibitors-not-linked-with-improved-survival-in-hospitalised-COVID-19-patients (2023).
Thiruvenkatarajan, V. et al. Peri-colonoscopy implications of sodium-glucose cotransporter-2 inhibitor remedy: a mini-review of obtainable proof. Can. J. Diabetes 47, 287–291 (2023).
Khunti, Okay. et al. Re-examining the widespread coverage of stopping sodium-glucose cotransporter-2 inhibitors throughout acute sickness: a perspective based mostly on the up to date proof. Diabetes Obes. Metab. 24, 2071–2080 (2022).
Raven, L. M., Muir, C. A. & Greenfield, J. R. Sodium glucose cotransporter 2 inhibitor-induced ketoacidosis is unlikely in sufferers with out diabetes. Med. J. Aust. 219, 293–294 (2023).
Hayes, A. G., Raven, L. M., Viardot, A., Kotlyar, E. & Greenfield, J. R. SGLT2 inhibitor-induced ketoacidosis in a affected person with out diabetes. Diabetes Care 47, e4–e5 (2024).
Duggan, A., Stewart, P. & Williams, D. Non-diabetic euglycaemic ketoacidosis secondary to SGLT2 inhibition. Coronary heart Lung Circ. 32, S167–S168 (2023).
Vukadinović, D. et al. Unwanted side effects and therapy initiation limitations of sodium–glucose cotransporter 2 inhibitors in coronary heart failure: a scientific assessment and meta-analysis. Eur. J. Coronary heart Fail. 24, 1625–1632 (2022).
Jardine, M. J. et al. Renal, cardiovascular, and security outcomes of canagliflozin by baseline kidney perform: a secondary evaluation of the CREDENCE randomized trial. J. Am. Soc. Nephrol. 31, 1128–1139 (2020).
Neuen, B. L., Jardine, M. J. & Perkovic, V. Sodium-glucose cotransporter 2 inhibition: which affected person with power kidney illness must be handled sooner or later? Nephrol. Dial. Transpl. 35, i48–i55 (2020).
Li, C. X. et al. Comparative security of various sodium-glucose transporter 2 inhibitors in sufferers with kind 2 diabetes: a scientific assessment and community meta-analysis of randomized managed trials. Entrance. Endocrinol. 14, 1238399 (2023).
Kang, A. et al. P1013. Canagliflozin and danger of genital infections and urinary tract infections in individuals with diabetes mellitus and kidney illness – a post-hoc evaluation of the CREDENCE trial. Nephrol. Dial. Transpl. 35, gfaa142 (2020).
Engelhardt, Okay., Ferguson, M. & Rosselli, J. L. Prevention and administration of genital mycotic infections within the setting of sodium-glucose cotransporter 2 inhibitors. Ann. Pharmacother. 55, 543–548 (2021).
Liu, J. et al. Results of SGLT2 inhibitors on UTIs and genital infections in kind 2 diabetes mellitus: a scientific assessment and meta-analysis. Sci. Rep. 7, 2824 (2017).
Butt, J. H. et al. Coronary heart failure, peripheral artery illness, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. Eur. Coronary heart J. 44, 2170–2183 (2023).
Fralick, M. et al. Fracture danger after initiation of use of canagliflozin: a cohort research. Ann. Intern. Med. 170, 155–163 (2019).
Patil, T., Prepare dinner, M., Hobson, J., Kaur, A. & Lee, A. Evaluating the security of sodium-glucose cotransporter-2 inhibitors in a nationwide Veterans Well being Administration observational cohort research. Am. J. Cardiol. 201, 281–293 (2023).
McEwan, P. et al. Price-effectiveness of dapagliflozin as a therapy for power kidney illness: a health-economic evaluation of DAPA-CKD. Clin. J. Am. Soc. Nephrol. 17, 1730–1741 (2022).
Igarashi, A. et al. Price-effectiveness evaluation of initiating kind 2 diabetes remedy with a sodium-glucose cotransporter 2 inhibitor versus standard remedy in Japan. Diabetes Ther. 13, 1367–1381 (2022).
Johnston, R. et al. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating kind 2 diabetes: systematic assessment and financial analysis. Well being Technol. Assess. 21, 1–218 (2017).
Sabapathy, S. et al. Price-effectiveness of canagliflozin versus sitagliptin when added to metformin and sulfonylurea in kind 2 diabetes in Canada. J. Popul. Ther. Clin. Pharmacol. 23, e151–e168 (2016).
Gourzoulidis, G. et al. Price-effectiveness of empagliflozin for the therapy of sufferers with kind 2 diabetes mellitus at elevated cardiovascular danger in Greece. Clin. Drug Investig. 38, 417–426 (2018).
Nguyen, E., Coleman, C. I., Nair, S. & Weeda, E. R. Price-utility of empagliflozin in sufferers with kind 2 diabetes at excessive cardiovascular danger. J. Diabetes Issues 32, 210–215 (2018).
Mettam, S. R., Bajaj, H., Kansal, A. R. & Kandaswamy, P. Price effectiveness of empagliflozin in sufferers with T2DM and excessive CV danger in Canada. Worth Well being 19, A674 (2016).
Daacke, I., Kandaswamy, P., Tebboth, A., Kansal, A. & Reifsnider, O. Price-effectiveness of empagliflozin (Jardiance) within the therapy of sufferers with kind 2 diabetes mellitus (T2DM) within the UK based mostly on EMPA-REG-OUTCOME knowledge. Worth Well being 19, A673 (2016).
Reifsnider, O. S. et al. Price-effectiveness of empagliflozin in sufferers with diabetic kidney illness in america: findings based mostly on the EMPA-REG OUTCOME trial. Am. J. Kidney Dis. 79, 796–806 (2022).
Jorissen, W., Annemans, L., Louis, N., Nilsson, A. & Willis, M. Well being financial modelling of diabetic kidney illness in sufferers with kind 2 diabetes handled with canagliflozin in Belgium. Acta Clin. Belg. 77, 945–954 (2022).
Willis, M. et al. Price-effectiveness of canagliflozin added to plain of look after treating diabetic kidney illness (DKD) in sufferers with kind 2 diabetes mellitus (T2DM) in England: estimates utilizing the CREDEM-DKD mannequin. Diabetes Ther. 12, 313–328 (2021).
Tisdale, R. L. et al. Price-effectiveness of dapagliflozin for non-diabetic power kidney illness. J. Gen. Intern. Med. 37, 3380–3387 (2022).
Kodera, S. et al. Price-effectiveness of dapagliflozin for power kidney illness in Japan. Circ. J. 86, 2021–2028 (2022).
Vareesangthip, Okay., Deerochanawong, C., Thongsuk, D., Pojchaijongdee, N. & Permsuwan, U. Price-utility evaluation of dapagliflozin as an add-on to plain of look after sufferers with power kidney illness in Thailand. Adv. Ther. 39, 1279–1292 (2022).
Lim, A. H., Abdul Rahim, N., Zhao, J., Cheung, S. Y. A. & Lin, Y. W. Price effectiveness analyses of pharmacological remedies in coronary heart failure. Entrance. Pharmacol. 13, 919974 (2022).
Gil-Rojas, Y., Lasalvia, P. & García, Á. Price-utility of dapagliflozin plus commonplace therapy in comparison with commonplace therapy for the administration of coronary heart failure with diminished ejection fraction in Colombia. Professional Rev. Pharmacoecon. Outcomes Res. 22, 655–663 (2022).
Isaza, N. et al. Price-effectiveness of dapagliflozin for the therapy of coronary heart failure with diminished ejection fraction. JAMA Netw. Open 4, e2114501 (2021).
Krittayaphong, R. & Permsuwan, U. Price-utility evaluation of add-on dapagliflozin therapy in coronary heart failure with diminished ejection fraction. Int. J. Cardiol. 322, 183–190 (2021).
& Liao, C.-T. et al. Price-effectiveness analysis of add-on empagliflozin in sufferers with coronary heart failure and a diminished ejection fraction from the healthcare system’s perspective within the Asia–Pacific Area. Entrance. Cardiovasc. Med. 8, 750381 (2021).
Liao, C.-T. et al. Price-effectiveness analysis of add-on dapagliflozin for coronary heart failure with diminished ejection fraction from perspective of healthcare methods in Asia–Pacific area. Cardiovasc. Diabetol. 20, 204 (2021).
Mohammadnezhad, G., Azadmehr, B., Mirheidari, M. & Yousefi, N. Price-effectiveness evaluation of dapagliflozin within the administration of coronary heart failure with diminished ejection fraction (HFrEF): a scientific assessment. Price Eff. Resour. Alloc. 20, 62 (2022).
Nguyen, B. N., Mital, S., Bugden, S. & Nguyen, H. V. Price-effectiveness of dapagliflozin and empagliflozin for therapy of coronary heart failure with diminished ejection fraction. Int. J. Cardiol. 376, 83–89 (2023).
Parizo, J. T. et al. Price-effectiveness of dapagliflozin for therapy of sufferers with coronary heart failure with diminished ejection fraction. JAMA Cardiol. 6, 926–935 (2021).
Reifsnider, O. S. et al. Price-effectiveness of empagliflozin within the UK in an EMPA-REG OUTCOME subgroup with kind 2 diabetes and coronary heart failure. Esc. Coronary heart Fail. 7, 3910–3918 (2020).
Sang, H., Wan, Y., Ma, Z., Zhang, S. & Zhao, Q. Price-effectiveness of empagliflozin for the therapy of coronary heart failure with diminished ejection fraction in China. Entrance. Cardiovasc. Med. 9, 1022020 (2022).
Cohen, L. P. et al. Price-effectiveness of sodium-glucose cotransporter-2 inhibitors for the therapy of coronary heart failure with preserved ejection fraction. JAMA Cardiol. 8, 419–428 (2023).
International Well being & Inhabitants Challenge on Entry to Look after Cardiometabolic Ailments Increasing entry to newer medicines for individuals with kind 2 diabetes in low-income and middle-income international locations: a cost-effectiveness and value goal evaluation. Lancet Diabetes Endocrinol. 9, 825–836 (2021).
The George Institute. The broader advantages of SGLT2 inhibitors. Well being TGIfG. https://www.georgeinstitute.org.au/our-impact/policy-and-recommendations/the-wider-benefits-of-sglt2-inhibitors 2021.
Mosenzon, O. et al. CAPTURE: a multinational, cross-sectional research of heart problems prevalence in adults with kind 2 diabetes throughout 13 international locations. Cardiovasc. Diabetol. 20, 154 (2021).
Arnold, S. V. et al. International use of SGLT2 inhibitors and GLP-1 receptor agonists in kind 2 diabetes. Outcomes from DISCOVER. BMC Endocr. Disord. 22, 111 (2022).
Nargesi, A. A. et al. Up to date nationwide patterns of eligibility and use of novel cardioprotective antihyperglycemic brokers in kind 2 diabetes mellitus. J. Am. Coronary heart Assoc. 10, e021084 (2021).
Homosexual, H. C. et al. Comparability of sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist prescribing in sufferers with diabetes mellitus with and with out heart problems. Am. J. Cardiol. 189, 121–130 (2023).
Ofori-Asenso, R. et al. Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real-world settings: proof from a scientific assessment and meta-analysis. Diabetes Metab. Res. Rev. 37, e3350 (2021).
Luo, J. et al. Incidence and predictors of major nonadherence to sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 agonists in a big built-in healthcare system. J. Gen. Intern. Med. 37, 3562–3569 (2022).
Vardeny, O. & Vaduganathan, M. Sensible information to prescribing sodium-glucose cotransporter 2 inhibitors for cardiologists. JACC: Coronary heart Fail. 7, 169–172 (2019).
Essien, U. R. et al. Affiliation of prescription co-payment with adherence to glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor therapies in sufferers with coronary heart failure and diabetes. JAMA Netw. Open 6, e2316290 (2023).
